GW Pharmaceuticals PLC Sponsored ADR
(NASDAQ : GWPH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SHPGShire PLC Sponsored ADR
0.62%177.410.4%$130.49m
PRGOPerrigo Co. Plc
-0.40%72.286.8%$97.68m
MNKMallinckrodt Plc
0.30%29.7621.1%$71.81m
JAZZJazz Pharmaceuticals Plc
-0.44%160.312.2%$69.52m
ENDPEndo International Plc
0.06%15.868.9%$59.69m
PTLAPortola Pharmaceuticals, Inc.
0.74%28.617.7%$40.85m
UTHRUnited Therapeutics Corporation
-0.46%125.3614.4%$38.98m
SAGESAGE Therapeutics, Inc.
1.08%146.709.6%$37.22m
CTLTCatalent Inc
0.28%42.692.4%$36.60m
ICPTIntercept Pharmaceuticals, Inc.
-0.18%118.5618.7%$31.06m
GWPHGW Pharmaceuticals PLC Sponsored ADR
2.09%143.886.8%$29.87m
ZGNXZogenix, Inc.
-0.72%48.1511.9%$29.64m
SUPNSupernus Pharmaceuticals, Inc.
4.02%47.856.2%$28.28m
MDCOMedicines Company
0.30%33.6621.8%$25.09m
ICLRICON Plc
0.63%146.194.2%$23.98m

Company Profile

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. It operates through the following segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the commercial products and promotes Sativex through collaborations with pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex, which are using the proprietary cannabinoid technology platform. The company was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.